Tinkering and Tailoring With Hcv Therapy: Can We Get Away With Less?
Open Access
- 24 November 2004
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 40 (6) , 1249-1251
- https://doi.org/10.1002/hep.20513
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- 93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled studyJournal of Hepatology, 2004
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?Journal of Hepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Effect of Treatment With Peginterferon or Interferon Alfa–2B and Ribavirin on Steatosis in Patients Infected With Hepatitis CHepatology, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusPublished by Elsevier ,1998